News stories about Innoviva (NASDAQ:INVA) have been trending positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Innoviva earned a media sentiment score of 0.40 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.8551753250127 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:

Innoviva (INVA) traded up $1.04 during midday trading on Friday, hitting $14.84. The stock had a trading volume of 779,757 shares, compared to its average volume of 874,499. The company has a market cap of $1,535.97, a PE ratio of 17.12 and a beta of 2.52. Innoviva has a 12 month low of $11.02 and a 12 month high of $16.11. The company has a quick ratio of 6.71, a current ratio of 6.71 and a debt-to-equity ratio of -2.59.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings data on Thursday, February 8th. The biotechnology company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.01. Innoviva had a negative return on equity of 33.55% and a net margin of 52.91%. The company had revenue of $69.52 million during the quarter, compared to analyst estimates of $67.41 million. During the same quarter last year, the firm posted $0.22 EPS. The firm’s revenue for the quarter was up 59.4% on a year-over-year basis. equities research analysts forecast that Innoviva will post 1.08 earnings per share for the current fiscal year.

Several equities analysts have weighed in on INVA shares. Zacks Investment Research upgraded Innoviva from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Wednesday, October 25th. Robert W. Baird restated a “hold” rating and set a $13.00 price objective on shares of Innoviva in a research note on Tuesday, October 24th. Deutsche Bank initiated coverage on Innoviva in a research note on Monday, November 20th. They set a “hold” rating and a $13.00 price objective on the stock. Cowen set a $16.00 target price on Innoviva and gave the stock a “buy” rating in a research note on Monday, October 23rd. Finally, BidaskClub upgraded Innoviva from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $13.50.

In related news, CFO Eric Desparbes sold 15,285 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $13.28, for a total value of $202,984.80. Following the completion of the sale, the chief financial officer now owns 337,027 shares in the company, valued at approximately $4,475,718.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP George B. Abercrombie sold 5,215 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $13.26, for a total value of $69,150.90. Following the completion of the sale, the vice president now owns 263,866 shares of the company’s stock, valued at approximately $3,498,863.16. The disclosure for this sale can be found here. In the last three months, insiders sold 32,522 shares of company stock valued at $429,985. 1.60% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.watchlistnews.com/innoviva-inva-earning-positive-press-coverage-report-finds/1855051.html.

Innoviva Company Profile

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Insider Buying and Selling by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.